Evidence map›Paper›PMID 35011613›Full record

ArticleCells2021

The Anti-Inflammatory Effect of the β1-Adrenergic Receptor Antagonist Metoprolol on High Glucose Treated Human Microvascular Retinal Endothelial Cells.

Giovanni Giurdanella, Anna Longo, Alfio Distefano, Melania Olivieri, Martina Cristaldi, Alessia Cosentino, Aleksandra Agafonova, Nunzia Caporarello, Gabriella Lupo, Carmelina Daniela Anfuso

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Vitamin DFrontiers in pharmacology · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Giovanni GiurdanellaBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-4855-8615
Anna LongoBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
Alfio DistefanoBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.ORCID 0000-0003-3323-9344
Melania OlivieriU.O. Clinical Pathology, Department of Hematology, AUSL Romagna, 47522 Cesena, Italy.
Martina CristaldiFidia Farmaceutici S.p.A., 95123 Catania, Italy.
Alessia CosentinoBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
Aleksandra AgafonovaBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.
Nunzia CaporarelloDepartment of Physiology & Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
Gabriella LupoBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.ORCID 0000-0002-9291-6969
Carmelina Daniela AnfusoBiochemistry Section, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-7951-1812
University of Catania · ITFidia Farmaceutici (Italy) · ITMayo Clinic in Florida · US

Funding

University of Catania University of Catania, Programma Ricerca di Ateneo Pia.Ce.Ri 2020-2022 linea 2, project number 57722172126.
6 · The paper itself

Abstract

Hyperglycemia-induced impairment of the blood-retinal barrier represents the main pathological event in diabetic retinopathy that is elicited by a reduced cellular response to an accumulation of reactive oxygen species (ROS) and increased inflammation. The purpose of the study was to evaluate whether the selective β1-adrenoreceptor (β1-AR) antagonist metoprolol could modulate the inflammatory response to hyperglycemic conditions. For this purpose, human retinal endothelial cells (HREC) were treated with normal (5 mM) or high glucose (25 mM, HG) in the presence of metoprolol (10 μM), epinephrine (1 μM), or both compounds. Metoprolol prevented both the HG-induced reduction of cell viability (MTT assays) and the modulation of the angiogenic potential of HREC (tube formation assays) reducing the TNF-α, IL-1β, and VEGF mRNA levels (qRT-PCR). Moreover, metoprolol prevented the increase in phospho-ERK1/2, phospho-cPLA

Indexed as

Adrenergic beta-1 Receptor AntagonistsAnti-Inflammatory AgentsCell NucleusCell ProliferationCyclooxygenase 2Down-RegulationEndothelial CellsEpinephrineGlucoseHeme Oxygenase-1HumansInterleukin-1betaKelch-Like ECH-Associated Protein 1MAP Kinase Signaling SystemMetoprololMicrovesselsAdrenergic beta-1 Receptor AntagonistsAnti-Inflammatory AgentsCyclooxygenase 2EpinephrineGlucoseHeme Oxygenase-1Interleukin-1betaKelch-Like ECH-Associated Protein 1MetoprololNF-E2-Related Factor 2Phospholipases A2, CytosolicReactive Oxygen SpeciesTumor Necrosis Factor-alphaVascular Endothelial Growth Factor Adiabetic retinopathy (DR)human retinal endothelial cells (HREC)Kelch-like ECH-associated protein 1 (Keap1)metoprololnuclear factor erythroid-2-related factor 2 (Nrf2)Phospholipase A2 (PLA2)β-Adrenergic Receptor (β-AR)

Identifiers

PMID35011613
PMCPMC8750370
OpenAlexW4200251802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.